MedTrace Logo

Nebulized Heparin for the Treatment of COVID-19

NCT04723563 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-09-05

No results posted yet for this study

Summary

Randomized, placebo controlled study to determine if nebulized heparin may reduce the need for mechanical ventilation in hospitalized patients with the novel coronavirus, also known as COVID-19. This will be a part of a larger meta-trial.

Conditions

  • Covid19
  • Pneumonia, Viral

Interventions

DRUG

Heparin

25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization

DRUG

0.9%sodium chloride

5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization

Sponsors & Collaborators

  • Frederick Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-22
Primary Completion
2021-08-23
Completion
2021-08-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04723563 on ClinicalTrials.gov